Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03196180 · ClinicalTrials.gov registry record · Early Phase 1
Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia
A Early Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Early Phase 1
- Development phase
- 13
- Enrollment target
NCT03196180: Completed Early Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT03196180 is a Early Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03196180, a Early Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This early phase I clinical trial studies the side effects of topical fluorouracil and imiquimod ointment in treating patients with high-grade cervical intraepithelial neoplasia. Topical fluorouracil may kill precancerous cells. Imiquimod ointment may stimulate the immune system. Applying topical fluorouracil and imiquimod ointment may cause fewer side effects and may be a better way to treat patients with precancerous cervical lesions.
Interventions
- DRUG Imiquimod
- DRUG Topical Fluorouracil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2019-10-15 |
| Est. Completion | 2024-08-02 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03196180
The ClinicalTrials.gov registry entry for NCT03196180 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Imiquimod is the first listed.
NCT03196180 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03196180 about?
NCT03196180 is a clinical study titled "Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia". This early phase I clinical trial studies the side effects of topical fluorouracil and imiquimod ointment in treating patients with high-grade cervical intraepithelial neoplasia. Topical fluorouracil may kill precancerous cells. Imiquimod ointment may stimulate the immune system. Applying topical fl...
What is the current status of trial NCT03196180?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 13 participants. The study started on 2019-10-15. Estimated completion is 2024-08-02.
What interventions are being tested in trial NCT03196180?
The interventions under investigation include: Imiquimod (DRUG), Topical Fluorouracil (DRUG).
Who is sponsoring clinical trial NCT03196180?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.